Drug Prices Will Now be Included in TV Ads as Part of Effort to Drive Costs Down

biospace | May 09, 2019

Drug Prices Will Now be Included in TV Ads as Part of Effort to Drive Costs Down
Television advertisements for prescription medications that are covered by Medicare or Medicaid will begin to display the list price of the drug. The rule, which has been favored by the White House and supported in Congress, was finalized Wednesday, Department of Health and Human Services Secretary Alex Azar said. If drug prices covered by the government-funded plans have a list price, the wholesale acquisition cost, greater than $35 for a month’s supply. The inclusion of the list price is part of an effort from the administration to lower the cost of prescription drugs.

Spotlight

iamicon 2016 - Hyderabad on November 12, 2016 Session : New Diagnostic Tools and Ways of Managing TB: Bench, Bedside and Beyond.

Spotlight

iamicon 2016 - Hyderabad on November 12, 2016 Session : New Diagnostic Tools and Ways of Managing TB: Bench, Bedside and Beyond.

Related News

Clarify Health Launches Next-Generation Analytics to Assist Pharmaceutical and Biotechnology Companies

Clarify Health | July 01, 2020

Clarify Health, a leading healthcare analytics company, announced that its life sciences software, Clarify Launch, now includes innovative enhancements that give brand teams a faster and more effective way to identify market opportunities to drive growth. The ability to explore over 300 million longitudinal patient care journeys using Clarify Launch offers brand teams rapid access to actionable insights within specific patient populations. Clarify brings first-of-their-kind patient segmentation, provider attribution, and provider scoring capabilities directly to end-users at pharmaceutical and biotechnology companies. “Two-thirds of new drugs fall short of first year implementation expectations, and they rarely rebound. Comprehensive next-generation analytics are uniquely positioned to help pharma and biotech companies alter this trend by providing a lens that crosses all stakeholders— patients, providers, and payers,” said Calum MacRae, M.D., Ph.D., Professor of Medicine at Harvard Medical School, and an advisor to Clarify Health.

Read More

AlzeCure Pharma provides a scientific update on Alzheimer's disease and the Alzstatin project platform

AlzeCure Pharma | September 28, 2020

CEO Martin Jönsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (Aβ) in the brain. Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University College of London (UCL), will participate and provide a deeper review of disease development in Alzheimer's and the amyloid hypothesis, as well as provide an update on developments in biomarkers and diagnostics in Alzheimer's.

Read More

KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development

KYAN Therapeutics, Inc. | September 24, 2020

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate Cancer. The low toxicity and metabolic stability of KYAN-001 indicates a better safety and tolerability profile than FDA approved pan-HDAC inhibitors which suffer from toxicity issues and side effects. KYAN-001 also uniquely inhibits HDAC4 nucleoshuttling to further drive its anti-cancer effects.

Read More